ACAD
41.69
+0.02
+0.05%
AEMD
6.9
-0.1
-1.43%
APRI
1.85
+0.17
+10.12%
ARNA
4.44
-0.03
-0.67%
ATEC
1.39
+0.01
+0.72%
CNAT
5.16
-0.08
-1.53%
CRXM
0.327
-0.033
-9.2778%
CYTX
0.548
-0.003
-0.5449%
DXCM
79.36
-0.41
-0.51%
GNMK
8.91
+0.16
+1.83%
HALO
22.1
-0.4
-1.78%
ILMN
220.07
-0.61
-0.28%
INNV
0.12
0.00
0.00%
INO
7.92
-0.22
-2.70%
ISCO
0.043
-0.004
-7.527%
ISIS
56.13
-1.03
-1.80%
LGND
98.6
+1.51
+1.56%
LPTN
0.275
-0.005
-1.6446%
MBVX
2.71
+0.19
+7.54%
MEIP
1.77
+0.07
+4.12%
MNOV
4.02
+0.09
+2.29%
MRTX
31.3
-0.39
-1.23%
MSTX
0.48
-0.01
-2.04%
NBIX
47.31
-0.35
-0.73%
NUVA
47.29
-0.23
-0.48%
ONCS
6.35
-0.25
-3.79%
ONVO
3.74
+0.03
+0.81%
OREX
4.76
-0.17
-3.45%
OTIC
22.09
-0.52
-2.30%
QDEL
23.01
+0.04
+0.17%
RCPT
194.91
-1.36
-0.69%
RGLS
10.2
-0.34
-3.23%
RMD
55.31
+0.01
+0.02%
SCIE
0.016
0.00
0.00%
SPHS
0.823
+0.04
+5.149%
SRNE
16.68
-0.53
-3.08%
TROV
9.53
-0.19
-1.95%
VICL
0.7
+0.015
+2.1752%
ZGNX
12.8
-1.16
-8.31%
ACAD
41.69
+0.02
+0.05%
AEMD
6.9
-0.1
-1.43%
APRI
1.85
+0.17
+10.12%
ARNA
4.44
-0.03
-0.67%
ATEC
1.39
+0.01
+0.72%
CNAT
5.16
-0.08
-1.53%
CRXM
0.327
-0.033
-9.2778%
CYTX
0.548
-0.003
-0.5449%
DXCM
79.36
-0.41
-0.51%
GNMK
8.91
+0.16
+1.83%
HALO
22.1
-0.4
-1.78%
ILMN
220.07
-0.61
-0.28%
INNV
0.12
0.00
0.00%
INO
7.92
-0.22
-2.70%
ISCO
0.043
-0.004
-7.527%
ISIS
56.13
-1.03
-1.80%
LGND
98.6
+1.51
+1.56%
LPTN
0.275
-0.005
-1.6446%
MBVX
2.71
+0.19
+7.54%
MEIP
1.77
+0.07
+4.12%
MNOV
4.02
+0.09
+2.29%
MRTX
31.3
-0.39
-1.23%
MSTX
0.48
-0.01
-2.04%
NBIX
47.31
-0.35
-0.73%
NUVA
47.29
-0.23
-0.48%
ONCS
6.35
-0.25
-3.79%
ONVO
3.74
+0.03
+0.81%
OREX
4.76
-0.17
-3.45%
OTIC
22.09
-0.52
-2.30%
QDEL
23.01
+0.04
+0.17%
RCPT
194.91
-1.36
-0.69%
RGLS
10.2
-0.34
-3.23%
RMD
55.31
+0.01
+0.02%
SCIE
0.016
0.00
0.00%
SPHS
0.823
+0.04
+5.149%
SRNE
16.68
-0.53
-3.08%
TROV
9.53
-0.19
-1.95%
VICL
0.7
+0.015
+2.1752%
ZGNX
12.8
-1.16
-8.31%
Home » Biography: Diana Wetmore, Ph.D.

Biography: Diana Wetmore, Ph.D.

Dr. Diana R. Wetmore is VP of Business Development and Alliances for Emerald BioStructures, and has an extensive background operating at the interface of business and science in the biotechnology and pharmaceutical industries. Her role at Emerald, a CRO providing structural biology services, includes building the client base through growth and diversification of services as well as business development support for ongoing projects. Prior to joining Emerald BioStructures, Dr. Wetmore was Vice President of Alliance Management for Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), where she managed the strategic planning process for the CF Foundation supported therapeutics pipeline, identified and launched multiple new discovery and development projects with industry collaborators. During this period her efforts helped shepherd many compounds and biologics into the clinical development pipeline. Prior to joining CFFT, Dr. Wetmore held positions in the pharmaceutical and biotechnology industries. At DuPont Merck Pharmaceuticals (now Bristol Myers Squibb), she was part of the crystallography group and studied protein-protein and protein-ligand interactions using calorimetric methods. During her 5-year tenure at Scriptgen Pharmaceuticals, now Anadys, she led the fragment discovery and drug design group before moving to Sr. Director of R&D Project Management. At Geneprot, Inc., she served as the Chief Technical Officer for that proteomics-based target discovery company. Dr. Wetmore obtained her PhD in biochemistry at the University of Calgary in Canada, where her interest was in studying the contributions of ligand binding to protein folding and stability. Her publications cover a range of scientific pursuits, including: protein biophysics, molecular modeling of target-ligand interactions, biomarker discovery and bioinformatics.